MRK241213C96000
- 5.30
- +0.40+8.16%
Merck & Co Newsroom
Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Merck & Co. Gets Key European Backing for Welireg in Two Uses
Express News | Merck: Final Decision Is Expected in Q1 of 2025
Express News | Merck Receives Positive EU Chmp Opinion for Welireg® (Belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
Express News | EMA's Chmp: Recommended Granting Conditional Marketing Authorisation for Welireg (Belzutifan)
Merck & Co To Go Ex-Dividend On December 16th, 2024 With 0.81 USD Dividend Per Share
December 12th (Eastern Time) - $Merck & Co(MRK.US)$ is trading ex-dividend on December 16th, 2024.Shareholders of record on December 16th, 2024 will receive 0.81 USD dividend per share on January 8th,
Trump rings the opening bell for the NYSE: The stock market is everything, and significant actions will be taken regarding Cryptos.
On Thursday, Donald Trump rang the opening bell at the NYSE. He emphasized the importance of the stock market, stating that the stock market is everything, and plans to take significant actions regarding Cryptos, lower the corporate tax rate to 15%, and increase Petroleum Extraction to alleviate the current inflationary pressures.
"Person of the Year" Trump rings the opening bell at the NYSE, emphasizing that "the stock market is everything."
On December 12, the elected President Trump was named Time Magazine's Person of the Year for 2024, ringing the opening bell at the NYSE that day; Trump rang the bell with the CEO of ICE and the CEO of Time Magazine, along with the president of the NYSE, while the CEOs of companies such as Goldman Sachs and Citigroup were present; Trump promised an "unprecedented economy," planned to increase oil drilling to reduce inflation, and committed to lowering the corporate tax rate to 15%.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Daily short sale tracking: Itau Unibanco's short volume increased by 7 million, with a short sale ratio of 16%
Itau Unibanco(ITUB.US) ranked top of the list had the largest change in short volume (7.08 million shares), and the short volume ratio of GlobalFoundries(GFS.US) reached 40.67%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Immutep Reports New Data In Head And Neck Cancer At ESMO Immuno-Oncology 2024; Complete Response Rate Increases To 12.9% And 16.1%, According To RECIST 1.1 And IRECIST, Respectively; Treatment Continues To Be Well Tolerated
Express News | The top category for the most disruptive products, Saxagliptin oral immediate-release formulation, ranked 33 to 9, with Huisheng Biotech proposed as the primary candidate for the bid.
CITIC Securities: Maintain the "Outperform Industry" rating for He Yu-B with a Target Price of HKD 6.76.
CICC released a research report stating that it maintains the forecast for Haoyu-B (02256) parent Net income for 2024 and 2025 at 2.13 million RMB and 2.7 million RMB unchanged. According to the DCF model, the bank maintains an outperform rating for the Industry and a Target Price of 6.76 HKD. On December 8, the company announced that it reported the preliminary phase II study results of Pimicotinib (ABSK021) for the treatment of 2L+ chronic graft-versus-host disease (cGvHD) at the 66th American Society of Hematology (ASH) annual meeting. Although most enrolled patients have not completed cGvHD relief.
Express News | The latest bid price for Sitagliptin tablets in collective procurement has dropped to below 0.2 yuan per tablet, a decline of over 90%.
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $121
Express News | Lynparza® (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in Olympia Phase 3 Trial